Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in...
Transcript of Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in...
![Page 1: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/1.jpg)
Results of Operations for the Fiscal Year Ended March 31, 2020
May 14, 2020Masaya Saito, Vice President
![Page 2: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/2.jpg)
Highlights of FY3/2020 Summary
Record‐high sales and earnings at all levelsPrior year included a one‐time contract payment from Shionogi & Co., Ltd. and there were higher business structural reform expenses, but earnings increased due to sales growth
Higher sales and earnings in Asia due to strong sales in the ASEAN countries
Limited impact of COVID‐19 on FY3/2020 results
Dividend increase for the 16th consecutive fiscal year Japan
Sales of high value‐added products remained strong Demand from foreign tourists in Japan started to decrease in 4Q
Solid sales at overseas subsidiaries in Asia Strong sales in the ASEAN region, but a negative effect of the yen’s
appreciation against the Chinese yuan
2
![Page 3: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/3.jpg)
FY3/2020Results of Operations
FY3/2020 Share of net sales (%) FY3/2019 YoY change
(Amount)YoY change
(%)
Net sales 188,327 100.0 183,582 4,745 2.6
Cost of sales 74,087 73,958 128 0.2Cost of sales rate 39.3 40.3SG&A expenses 91,154 48.4 88,812 2,342 2.6
Promotional expense
23,533 12.5 23,086 446 1.9
Advertisement 24,394 13.0 24,593 △198 △0.8R&D Exp 7,050 3.7 6,831 219 3.2Others 36,175 19.2 34,300 1,875 5.5
Operating income 23,085 12.3 20,812 2,273 10.9Ordinary income 22,735 12.2 18,970 3,764 19.8
Profit attributable to owners of parent 15,410 8.2 9,799 5,610 57.3
3
(Millions of yen, rounded down)
Exchange Rate:〔US$/Yen〕=109.05
![Page 4: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/4.jpg)
Sales are Driving Earnings Growth!
4
Cost of sales
Sales promotion expenses
Advertising expenses
R&D expenses
Other SG&A expenses
FY3/2020Operating income
FY3/2019Operating income
(Millions of yen)
![Page 5: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/5.jpg)
Five‐year Financial Summary
5
Net sales Operating income ROE
5-year average growth rate: 4.6%
Operating margin
12.2%5-year average
8.7%億円 億円
%
![Page 6: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/6.jpg)
Quarterly sales trends
6
![Page 7: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/7.jpg)
Quarterly Operating Income trends
7
![Page 8: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/8.jpg)
8
Operating CF Investing CF Financing CF
Cash Flows
Positive Free Cash Flow Sustained While Making Medium and Long‐term Investments
(Millions of yen)Net increase (decrease) in cash and cash equivalents
‐‐‐
‐‐
‐
‐
‐
‐
![Page 9: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/9.jpg)
FY3/2020 Sales by Reportable Segment
9
(Millions of yen, rounded down)
AmountShare of net
sales (%)Amount
Share of netsales (%)
AmountShare of net
sales (%)YoY change(Amount)
YoY change(%)
171,742 100.0 183,582 100.0 188,327 100.0 4,745 2.6
105,242 61.3 112,166 61.1 115,767 61.5 3,601 3.2
47,396 27.6 51,664 28.1 52,971 28.1 1,306 2.5
8,750 5.1 9,293 5.1 9,121 4.8 △ 171 △ 1.8
8,277 4.8 8,555 4.7 8,740 4.6 185 2.2
169,666 181,679 186,601
2,076 1.2 1,903 1.0 1,726 0.9 △ 177 △ 9.3
* Net sales indicate sales to customers.
Others
Exchange rate(Yen/USD)
111.43 110.48 109.05
Reporta
ble
segm
ent
Japan
Asia
America
Europe
Total
FY3/2018 FY3/2019 FY3/2020
Net sales
![Page 10: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/10.jpg)
(Millions of yen, rounded down)
AmountShare of net
sales (%)Amount
Share of netsales (%)
AmountShare of net
sales (%)YoY change(Amount)
YoY change(%)
19,087 100.0 20,812 100.0 23,085 100.0 2,272 10.9
12,223 64.0 13,181 63.3 14,852 64.3 1,671 12.7
5,670 29.7 6,497 31.2 7,220 31.3 723 11.1
420 2.2 286 1.4 283 1.2 △ 2 △ 0.8
305 1.6 352 1.7 217 0.9 △ 135 △ 38.3
18,619 20,317 22,573
157 0.8 163 0.8 142 0.6 △ 21 △ 13.0
310 1.6 330 1.6 369 1.6 38
Others
Exchange rate(Yen/USD) 111.43 110.48
Adjustment
109.05
Report
able
segm
ent
Japan
Asia
America
Europe
Total
FY3/2018 FY3/2019 FY3/2020
Net sales
FY3/2020 Operating Income by Reportable Segment
10
![Page 11: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/11.jpg)
Japan: Higher Sales, Lower Profits Sales of high value‐added
products remained strong
Strong sales of trending new products
Demand from foreign tourists in Japan decreased
CDMO contributed to higher sales and profit
11
![Page 12: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/12.jpg)
Big Increase in Sales ofHigvalue‐added Products!
12
VRohto Premium series
obagiC25
episteme
![Page 13: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/13.jpg)
Strong sales of major new products
13
Rohto V5 Grain
DEOCO
![Page 14: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/14.jpg)
Inbound Sales about 2.8 Billion Yen
14
Sales to foreign tourists in Japan decreased because of COVID‐19
Inbound sales
Highly popular Melano CC series
episteme STEM SCIENCE drink
![Page 15: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/15.jpg)
Higher Sales and Profits in Asia
Sales were higher in the ASEAN countries Malaysia 30% higher Vietnam 15% higher Indonesia 10% higher
Sales were lower in China and Hong Kong Protests in Hong Kong Yen’s appreciation against
Chinese yuan Strong sales in Taiwan Steady growth in
e‐commerce sales
15
(100 millions of yen)530517
474
419
Hong Kong, China, Taiwan
Others
FY3/2017 FY3/2018 FY3/2019 FY3/2020
![Page 16: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/16.jpg)
E‐commerce Initiatives in China
E‐commerce sales in ChinaStrengthening internet activities to raise e‐commerce to 30% of total sales
Growth is continuing in 2020; growth rate is more than 30% based on shipments
Strengthen cross‐bordere‐commerceMelano CC seriesepistemeCareCera and others
16
episteme STEM SCIENCE drink
![Page 17: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/17.jpg)
America, Europe and Others
America Sales: ¥9,121 million, down 1.8% YoYOperating profit: ¥283 million, down 0.8% YoY
Intense competition for eye dropsRohtoCoolMax
Europe Sales: ¥8,740 million, up 2.2% YoYOperating profit: ¥217 million, down 38.3% YoY
Strong Deep Relief sales Lower earnings due to higher
sales promotion expenses Dax Cosmetics sales
increased
17
Deep Relief series Perfecta series
![Page 18: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/18.jpg)
Outlook for FY3/2021
18
May 14, 2020Kunio Yamada, Chairman and President Masashi Sugimoto, President and COO
![Page 19: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/19.jpg)
Highlights of FY3/2021 Forecast
Forecast lower sales and earnings due to COVID‐19
The forecast reflects the impact of COVID‐19 and Rohto’s responses to this crisis
Measures for sustained medium and long‐term growthMake core businesses stronger Respond to changes in consumer behavior Activities involving regenerative medicine and prescription
ophthalmology drugs
Forecast the 17th consecutive dividend increase
19
![Page 20: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/20.jpg)
(Millions of yen, rounded down)
FY3/2019Share of net
sales (%)FY3/2020
Share of netsales (%)
FY3/2021Forecast
Share of netsales (%)
YoY change(%)
Net Sales 183,582 100.0 188,327 100.0 183,000 100.0 △ 2.8
Operating income 20,812 11.3 23,085 12.3 21,800 11.9 △ 5.6
Ordinary income 18,970 10.3 22,735 12.1 22,100 12.1 △ 2.8
Profit attributableto owners of
parent9,799 5.3 15,410 8.2 14,000 7.7 △ 9.2
Net Income per Share 86.00 135.13 122.73
FY3/2021 Forecast
20
109.05110.48 107
![Page 21: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/21.jpg)
FY3/2021 Sales Forecast by Reportable Segment
21
(Millions of yen, rounded down)
AmountShare of net
sales (%)Amount
Share of netsales (%)
AmountShare of net
sales (%)YoY change
(Amount)YoY change
(%)
183,582 100.0 188,327 100.0 183,000 100.0 △ 5,328 △ 2.8
112,166 61.1 115,767 61.5 114,100 62.3 △ 1,668 △ 1.4
51,664 28.1 52,971 28.1 50,700 27.7 △ 2,272 △ 4.3
9,293 5.1 9,121 4.8 8,500 4.6 △ 622 △ 6.8
8,555 4.7 8,740 4.6 8,100 4.4 △ 641 △ 7.3
181,679 186,601 181,400
1,903 1.0 1,726 0.9 1,600 0.9 △ 127 △ 7.4
* Net sales indicate sales to customers.
FY3/2019 FY3/2020 FY3/2021Forecast
Net sales
Reportable
segm
ent
Japan
Asia
America
Europe
Total
Others
Exchange rate(Yen/USD)
110.48 109.05 107.00
![Page 22: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/22.jpg)
FY3/2021 Operating Income Forecast by Reportable Segment
22
(Millions of yen, rounded down)
AmountShare of net
sales (%)Amount
Share of netsales (%)
AmountShare of net
sales (%)YoY change
(Amount)YoY change
(%)
20,812 100.0 23,085 100.0 21,800 100.0 △ 1,286 △ 5.6
13,181 63.3 14,852 64.3 14,300 65.6 △ 553 △ 3.7
6,497 31.2 7,220 31.3 6,700 30.7 △ 521 △ 7.2
286 1.4 283 1.2 200 0.9 △ 84 △ 29.5
352 1.7 217 0.9 100 0.5 △ 118 △ 54.0
20,317 22,573 21,300
163 0.8 142 0.6 100 0.5 △ 43 △ 29.8
Adjustment 1.6 369 1.6 400 1.8
107.00
Others
Exchange rate(Yen/USD) 110.48 109.05
Reporta
ble
segm
ent
Japan
Asia
America
Europe
Total
FY3/2019 FY3/2020 FY3/2021Forecast
Net sales
![Page 23: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/23.jpg)
Impact of COVID‐19 and Rohto’s Responses to This Crisis
23
![Page 24: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/24.jpg)
Impact of COVID‐19 and Rohto’s Responses to This Crisis1. Short‐term impact on business activities Concerns about lower sales of sunscreen products and other skin care
products because people are staying home for safety Sluggish demand from foreign tourists in Japan
2. Production No negative effect on production activities in Japan and China, the
primary locations of Rohto’s manufacturing bases Production is starting to recover in Europe and the U.S.
3. Internal activities Health management programs, including assistance to stop smoking Use of off‐peak commuting and teleworking
4. Support for COVID‐19 activities Established the COVID‐19 Medical Institution Support Office
24
![Page 25: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/25.jpg)
Short‐term Impact on Business Activities
Sales in Japan Limited effect on sales at drug stores and
convenience stores because these stores remain open
Strong Amazon and other e‐commerce sales
Emerging need for skin care products to prevent skin problems caused by wearing masks
Sales are declining at general merchandise stores
Concerns about lower sales of sunscreen and other products as people stay home
Lower demand from foreign tourists in Japan
Overseas Sales Lockdowns are affecting
sales, but sales in some regions are beginning to recover Firm sales in Vietnam and
Indonesia Sales are recovering in China Uncertain outlook for Europe
and the U.S.
E‐commerce sales are increasing in all regions
25
![Page 26: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/26.jpg)
Effects on Production and Distribution
Production Operations restarted in the middle of February in China No significant problems in Japan Lockdowns are affecting Europe and U.S. production; but as a
manufacturer of pharmaceuticals, Rohto is generally exempt from restrictions
Procurement and distribution No significant problems involving raw materials and finished
product inventories in the core markets of Japan and China In Japan, no major concerns involving procurement activities
because Rohto has very few products like disinfectants where COVID‐19 has created higher demand
In the U.S., Mentholatum sales are brisk for easing cold symptoms and there may be a shortage of containers for this product
26
![Page 27: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/27.jpg)
COVID‐19 Countermeasures and Business Continuity Measures to secure employee health and safety
Constant programs for staying healthy ‐Place priority on health management‐• 99.9% of the Rohto workforce does not smoke• Consistently provide information to make employees aware of COVID‐19 precautions
Temperature and other changes in health are checked every morning and reported using a system
Use of off‐peak commuting and teleworking• As a rule, people work at home and go to their workplaces less than 30% as often as usual
• Workplace access is restricted to employees of the workplace department or section (production, logistics, IT systems, etc.)
Established the COVID‐19 Medical Institution Support Office Rohto is giving medical institutions medical‐grade masks and protective apparel at no cost
to support people at the front line of the COVID‐19 response. Support also includes hand cream and other Rohto products
Rohto supports the Japan Heart Social Network, a project that distributes COVID‐19 response supplies to healthcare professionals
27
![Page 28: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/28.jpg)
Outlook and Measures for Sustained Medium and Long‐term Growth
28
![Page 29: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/29.jpg)
Measures for Sustained Medium and Long‐term GrowthMake core businesses stronger
Reinforce business process reforms and make reforms self‐sustaining Upgrade and expand production equipment Strengthen corporate governance
Respond to changes in consumer behavior Pre‐symptomatic and prevention initiatives Responses to the increase in teleworking and other changes due to
COVID‐19
Measures for sustained growth Progress in the regenerative medicine field Activities to start selling prescription drugs Start and expand operations in emerging countries
29
![Page 30: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/30.jpg)
Make Core Businesses Stronger
Reinforce business process reforms and make reforms self‐sustaining Improvement in cost of sales ratio
Reduce the product return ratio Increase the share of products that are manufactured internally Reexamine the procurement of raw materials and finished
products
Effective use of SG&A expenses Use digital advertising channels to lower the advertising expense
ratio Combine brands and items
30
Build a framework for business process reforms that do not rely on external knowledge
![Page 31: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/31.jpg)
Upgrade and Expand Production Equipment
Aim for annual energy use of at least 20% less than at existing Rohto factories
31
Global GMP
Constructing a “smart” factory at the Ueno Techno Center (Mie prefecture) with measures for the workforce and environmental responsibility (to be completed in 2022)
Kind to peopleKind to the environment
Global Good Manufacturing
Practices
Energy sources
Renewable energy Energy‐efficient equipment
Geothermal energy Solar energy Efficient HVAC/gas/electric equipment
![Page 32: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/32.jpg)
Strengthen Corporate Governance
More powerful structure for managementChange to six internal directors and three external directors making up the Board of Directors
Establish an executive officer systemSeparation of supervisory and executive functions
Strengthen the roles of external directors and external Audit & Supervisory Board members
Establish a provision for the position of substitute Audit & Supervisory Board member
Reduce investment securities Sell investment securities to fund part of the cost of acquiring Nitten Pharmaceutical Co., Ltd.
32
![Page 33: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/33.jpg)
Respond to Changes in Consumer Behavior
Responses to changes in people’s behavior Growth of teleworking
• Meet the need for products for eye fatigue caused by the increasing use of PCs, tablets and smartphones
Growth of self‐medication• People are using more OTC drugs for health issues associated with activities to prevent COVID‐19, such as skin problems caused by frequent hand washing
Increase activities in the pre‐symptomatic and preventive domains
Place priority on health management
33
A source of even better products and information as a healthcare company able to help people stay healthy
![Page 34: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/34.jpg)
Regenerative Medicine/Prescription Drug ActivitiesProgress in the regenerative medicine fieldStarted physician‐supervised trials concerning heart failure
Business for contract cell processing and productionAlliance with Human Life CORD Japan
Prescription ophthalmology drug activitiesUse of Nitten Pharmaceutical Co., Ltd.Business alliance with Wakamoto Pharmaceutical
34
![Page 35: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/35.jpg)
2019 2020 2021 2022 2023 2024Products
Adipose MSC
Liver cirrhosis
Heart failure
Kidney disease
Limb ischemia
Pulmonary fibrosis
Bone&joint disease
Umbilical cord MSC
NeurologicaldisorderAutomated system
Unit1
Unit2DevelopDevelopment In operation
Clinical studies
Clinical studies
Clinical studies
Clinical studiesPre‐
studies
Pre‐Clinical studies
Clinical studies
Clinical studies
Clinical studies
In operation
Development Pipeline
Pre‐Clinical studies
P Cli i lstudies
Pre‐Clinical studies
P Cli i lstudies
Pre‐Clinical studies
l lPre‐Clinical studiesPre‐
studies
Pre‐Clinical studies
![Page 36: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/36.jpg)
Cell Spray Heart Failure Treatment
An Osaka University Hospital research team led by Prof. Yoshiki Sawa has developed the cell spray therapy, in which cells are directly applied to the surface of the heart.
A physician‐supervised trial (Phase I) for ADR‐002K started in November 2019 for the treatment of ischemic cardiomyopathy.
Rohto started a joint research program with this research team in 2016. This program has succeeded in developing a simple spraying technology using cells that are prepared at the time of use. This technology uses human allogeneic adipose‐derived mesenchymal stem cells with uniform characteristics and quality.
36
Allogenic Adipose‐derived Stem Cells
Fibrin Sealant
Current drugs
![Page 37: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/37.jpg)
Business Alliances
Progress of contract cell processing and production business Alliance with Human Life CORD Japan and Alfresa
The purpose of this alliance is the development of a drug using mesenchymal stem cells that are derived from umbilical cords, a project now under way at Human Life CORD Japan. The three companies have started conducting studies on ways to accomplish this goal.
Activities to start selling prescription drugs Use of Nitten Pharmaceutical Co., Ltd. Business alliance with Wakamoto Pharmaceutical
Joint development and sale of prescription ophthalmology drugs Joint development and sale of OTC drugs and health food products
using the lactic acid bacteria expertise of Wakamoto Pharmaceutical
37
![Page 38: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/38.jpg)
Start and Expand Operations in Emerging Countries Establish bases for operations in Eastern Europe and Russia
Plan to use Dax Cosmetics as the base for operations in Eastern Europe
Establish a local subsidiary in Russia
Middle East Invested in Rebul, which is based in Turkey
COVID‐19 has sparked a big increase in demand for kolonya, a traditional Turkish eau de cologne. Kolonya was recognized effective for disinfection because of its high ethanol content.
South America Reorganized a subsidiary in Brazil
Downsize business activities in India and Bangladesh
38
![Page 39: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/39.jpg)
Forecast the 17th Consecutive Dividend Increase
39
円
![Page 40: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/40.jpg)
Impact of COVID‐19 Crisis on Operations
Achieved record‐high sales and earnings• Higher sales and earnings in Japan ana Asia
• Limited impact of COVID‐19
• Impact of consumption tax hike• Concern over the growing US‐China trade friction
• Warm winter and weather factors• Decrease in demand from foreign tourists in Japan
Forecast lower sales and earnings ‐ Dramatic change in the business climate!• Impact of COVID‐19
Worldwide decline in consumer spending and changes in consumer behavior
• Use a long‐term perspective for managementA more powerful infrastructureA sound financial positionRespond to changes in consumer needs and preferenceInvestments for a longer healthy life
FY3/2020 FY3/2021
![Page 41: Results of Operations for theFiscal Year Ended March 31, 2020 · Chinese yuan Strong sales in Taiwan Steady growth in ... Intense competition for eye drops RohtoCoolMax Europe Sales:](https://reader036.fdocuments.in/reader036/viewer/2022071013/5fcc22bbef0c0079932c6f51/html5/thumbnails/41.jpg)
41
PrecautionsThe plans, strategies, and financial forecasts presented in these materials contain forward‐looking statements not based on historical fact. Forward‐looking statements are based on management judgments using information available at the time. Actual results may vary significantly from forecasts due to changes in various factors.